RE: Follow the money!15 Oct 2020 20:35
Going through the Rns for the fourth time and this paragraph has me nibbling at my dark chocolate Lake District cookie and having a satisfying glut of tea.
As a result of this acquisition, Novacyt will become a diagnostic platform instrument and reagent manufacturer and will significantly increase the manufacturing capability of IT-IS to manage the expected demand for its q16 and q32 PCR instruments. As a result of higher manufacturing volume, the Company expects to reduce its cost of goods and therefore improve the gross margin of its instrument sales.
Significantly increase the manufacturing capability.....nice.